ArticleEuropean journal of nuclear medicine and molecular imaging2025
Robust and interpretable deep learning system for prognostic stratification of extranodal natural killer/T-cell lymphoma.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Deep learning-based PET/CT mixture-of-experts model for relapse risk stratification in relapsed/refractory classical hodgkin lymphoma: a multicenter study.European journal of nuclear medicine and molecular imaging · 2026Article
- Applications of artificial intelligence in nuclear medicine.Zeitschrift fur medizinische Physik · 2026Review
- Multi-Modal Ultrasound-Based Prognostic Model for Diffuse Large B-Cell Lymphoma with Predominantly Superficial Lymph Node Involvement.Diagnostics (Basel, Switzerland) · 2026Article
- A clinical-radiomic model based on best subset regression for prognostic prediction in natural killer/T-cell lymphoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Peritumoral habitat radiomics predicts axillary lymph node metastasis in breast cancer.iScience · 2026Article
- Artificial intelligence reshaping the paradigm of hematologic malignancy diagnosis and treatment: From static assessment to dynamic precision management.Annals of hematology · 2026Review
- Prognostic value of a combined model integrating clinical and PET radiomics parameters in metastatic melanoma: A dual-center retrospective study.Annals of nuclear medicine · 2026Article
- EffAtt-LungNet: An attention-guided EfficientNet framework for three-class lung histopathology classification.PloS one · 2026Article
- An interpretable machine learning model for predicting bone marrow invasion in patients with lymphoma viaBMC medical informatics and decision making · 2025Article
- The Usefulness of 2-[18F]FDG PET or PET/CT in Extranodal Natural Killer/T-Cell Lymphoma: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeExtranodal natural killer/T-cell lymphoma (ENKTCL) is an hematologic malignancy with prognostic heterogeneity. We aimed to develop and validate DeepENKTCL, an interpretable deep learning prediction system for prognosis risk stratification in ENKTCL.
methodsA total of 562 patients from four centers were divided into the training cohort, validation cohort and test cohort. DeepENKTCL combined a tumor segmentation model, a PET/CT fusion model, and prognostic prediction models. RadScore and TopoScore were constructed using radiomics and topological features derived from fused images, with SHapley Additive exPlanations (SHAP) analysis enhancing interpretability. The final prognostic models, termed FusionScore, were developed for predicting progression-free survival (PFS) and overall survival (OS). Performance was assessed using area under the receiver operator characteristic curve (AUC), time-dependent C-index, clinical decision curves (DCA), and Kaplan-Meier (KM) curves.
resultsThe tumor segmentation model accurately delineated the tumor lesions. RadScore (AUC: 0.908 for PFS, 0.922 for OS in validation; 0.822 for PFS, 0.867 for OS in test) and TopoScore (AUC: 0.756 for PFS, 0.805 for OS in validation; 0.689 for PFS, 0.769 for OS in test) both exhibited potential prognostic capability. The time-dependent C-index (0.897 for PFS, 0.928 for OS in validation; 0.894 for PFS, 0.868 for OS in test) and DCA indicated that FusionScore offers significant prognostic performance and superior net clinical benefits compared to existing models. KM survival analysis showed that higher FusionScores correlated with poorer PFS and OS across all cohorts.
conclusionDeepENKTCL provided a robust and interpretable framework for ENKTCL prognosis, with the potential to improve patient outcomes and guide personalized treatment.
Indexed as
Identifiers
39714634What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.